ACTG 5178: SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS

ACTG 5178：丙型肝炎病毒的抑制性长期抗病毒治疗

• 批准号: 7378723
• 负责人: WILLIAM AUSTIN O'BRIEN
• 金额: $ 0.14万
• 依托单位: UNIVERSITY OF TEXAS MED BR GALVESTON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378723
• 关键词: ACTG; 5178; SUPPRESSIVE; LONG; TERM

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Background: The purpose of this study is to find out whether long-term treatment with pegylated-interferon (PEG-IFN) slows the rate of liver damage caused by hepatitis C in people also infected with HIV. Specific Aims and Procedures (summary): Part 1: Participants will be given PEG-IFN and ribavirin for 12 weeks if they have never been treated for HCV; they have been treated in the past with PEG-IFN, IFN or IFN and ribavirin for up to one year, but have been off treatment for 12 weeks; or they have been treated with some form of IFN for at least 12 weeks and still have HCV. After 12 weeks of treatment, all participants will have a liver biopsy. Part 2: Participants who do not show signs of responding to the 12 weeks of treatment will be assigned by chance to either receive PEG-IFN alone for 72 weeks or to continue on study off treatment for 72 weeks. Part 3: Participants who sign signs of responding to the 12 weeks of treatment will continue to receive PEG-IFN and ribavirin for 72 weeks and then be followed on study for an additional 24 weeks off treatment. Significance (summary): Study findings will be available to participants.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。背景：本研究的目的是查明长期使用聚乙二醇化干扰素 (PEG-IFN) 治疗是否可以减缓同时感染 HIV 的丙型肝炎引起的肝损伤的速度。 具体目标和程序（摘要）：第 1 部分：如果参与者从未接受过 HCV 治疗，将给予 PEG-IFN 和利巴韦林 12 周；他们过去曾接受 PEG-IFN、IFN 或 IFN 和利巴韦林治疗长达一年，但已停止治疗 12 周；或者他们已经接受某种形式的 IFN 治疗至少 12 周，但仍然患有 HCV。治疗 12 周后，所有参与者都将进行肝活检。 第 2 部分：未显示出对 12 周治疗有反应迹象的参与者将被随机分配接受单独 PEG-IFN 治疗 72 周或继续接受治疗 72 周的研究。 第 3 部分：在 12 周的治疗中表现出反应迹象的参与者将继续接受 PEG-IFN 和利巴韦林治疗 72 周，然后在治疗结束后的另外 24 周内继续进行研究。 意义（摘要）：研究结果将提供给参与者。